Galleri Revenue Up 14% but Net Loss Widens to $103.6M; FDA Decision Due Early Q1 2027
GRAL has more than doubled off its 52-week low of $41.5.
Summary
Galleri revenue rose 14% year-over-year to $37.3 million, but total revenue grew only 4% to $37.5 million as development services revenue collapsed to $266 thousand from $3.4 million. The bottom line deteriorated: net loss widened 16% to $103.6 million and adjusted EBITDA loss grew 29% to $92.6 million, while adjusted gross margin fell to 42% from 55%. Sales and marketing spending jumped to $41.7 million from $25.5 million, and cost of screening revenue rose to $22.0 million from $15.9 million, so volume growth is coming at a heavy cost. Cash, equivalents and short-term marketable securities totaled $788.7 million at September 30, down from roughly $904 million at year-end 2025 — a burn rate that keeps financing risk on the table. The company reiterated it expects an FDA decision on Galleri by early Q1 2027, following the September advisory committee vote in favor and the NEJM/Nature Medicine publications.
At the time of this announcement, GRAL was trading at $135.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $41.50 to $166.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.